Transcend Therapeutics | pharmaphorum

Skip to main content

Saturday 24 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Transcend Therapeutics

News

FDA grants three priority vouchers to psychedelics

FDA grants three priority vouchers to psychedelics

The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.

News

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.

Editor's Picks

CHMP backs Lilly's oral GLP-1 Foundayo for EU approval

RevMed nears EU okay for pancreatic cancer drug Rasonque

Roche adds another obesity drug with $1.16bn Rona deal

MHRA lays out its thinking on AI and medicines regulation

GSK planning 1,200 job cuts in Belgium, says paper

News

ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer

ESMO26: Zai and Ideaya showcase DLL3 drugs in lung cancer

Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new trial readouts at ESMO.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company